Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is myxofibrosarcoma?
Myxofibrosarcoma is one of the most common soft-tissue sarcomas in older adults. A sarcoma is a cancer that arises in the body's connective tissues rather than in an organ lining; myxofibrosarcoma arises in fibrous tissue and is named for its 'myxoid' (gel-like) appearance under the microscope. It most often appears in or just beneath the skin of an arm or leg as a slowly enlarging, usually painless mass, and because it can feel soft and grow gradually it is sometimes mistaken for a harmless lump. What makes myxofibrosarcoma distinctive — and challenging — is its growth pattern: it sends long, microscopic, finger-like 'tails' of tumor cells creeping through the surrounding tissue far beyond the edge of the mass that can be seen or felt. These infiltrative tails are the single most important feature of the disease, because they are easy to leave behind during surgery, and they are the reason myxofibrosarcoma has one of the highest tendencies of any sarcoma to come back where it started if it is not treated thoroughly. The tumor ranges from low-grade (slow-growing and unlikely to spread) to high-grade (more aggressive and able to spread, most often to the lungs). The cornerstone of treatment is surgery to remove the tumor with a generous margin of healthy tissue, guided by MRI to map the extent of those tails. Radiation is very commonly combined with surgery — before or after — precisely to treat the wide zone of microscopic disease that the scalpel cannot fully reach, which substantially lowers the chance of local recurrence. Chemotherapy is reserved for selected high-grade tumors at higher risk of spreading and for disease that has already spread.
The main types
Doctors group myxofibrosarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Low-grade myxofibrosarcoma | A slow-growing tumor that rarely spreads but is still locally infiltrative and prone to coming back; treated with wide surgery, often plus radiation, and careful long-term follow-up. |
| Intermediate-grade myxofibrosarcoma | A middle category that can recur locally and, less often, spread; generally treated with surgery and radiation, sometimes progressing to higher grade if it recurs. |
| High-grade myxofibrosarcoma | An aggressive tumor that can spread, most often to the lungs; treated with wide surgery and radiation, with chemotherapy considered because of the higher risk of spread. |
| Superficial (skin / subcutaneous) myxofibrosarcoma | The typical location, in or just under the skin of a limb; the infiltrative tails are still the main challenge, so radiation is often added to surgery to control microscopic disease. |
Staging, in plain terms
Myxofibrosarcoma is staged with the soft-tissue sarcoma TNM system, and the grade is especially informative. Grade describes how aggressive the cells look under the microscope and how likely the tumor is to spread: low-grade tumors rarely spread but are still locally infiltrative and prone to recurrence, while high-grade tumors can travel to distant organs, most often the lungs. The T category reflects the size and depth of the tumor, with larger and deeper tumors carrying more risk; the N category notes lymph-node involvement, which is uncommon; and the M category notes distant spread. Because high-grade disease spreads through the bloodstream to the lungs, a CT scan of the chest is part of staging and follow-up. What stage and grade do not fully capture, however, is the feature that most shapes treatment day to day: the tumor's long microscopic tails. MRI is used to map how far these infiltrative extensions reach, because they determine how wide the surgery and the radiation field need to be. In practice, the key questions are the grade, the size and depth of the mass, how far the infiltrative tails extend on imaging, and whether there is any spread. The answers determine how generous the surgical margin must be, how the radiation field is designed, and whether chemotherapy is considered.
| Soft-tissue sarcoma TNM with grade — tumor size and depth (T), lymph nodes (N), distant spread (M), and grade, which strongly drives behavior | What it generally means |
|---|---|
| Low-grade, localized | A slow-growing tumor confined to its site that rarely spreads; treated with wide surgery and often radiation, with long-term follow-up because of the high tendency to recur locally. |
| High-grade, localized, smaller | A more aggressive tumor still confined to its site; treated with wide surgery and radiation to control the infiltrative microscopic disease and lower recurrence risk. |
| High-grade, localized, larger or deep | A big or deep high-grade tumor; treated with wide surgery and radiation, with chemotherapy considered because of the higher risk of later spread. |
| Metastatic (usually lungs) | Cancer that has spread, most often to the lungs; treated with systemic therapy, with surgery or focused radiation for a limited number of deposits. |
The standard of care
Myxofibrosarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Wide surgical removal
Removing the tumor with a generous margin of healthy tissue, guided by MRI mapping of the infiltrative tails — the central treatment, designed to capture microscopic disease that extends well beyond the visible mass.
Radiation therapy (before or after surgery)
Very commonly combined with surgery to treat the wide zone of microscopic 'tails'; it allows limb-preserving operations and substantially lowers myxofibrosarcoma's high chance of returning locally.
MRI mapping of tumor extent
Detailed imaging before surgery shows how far the infiltrative tails reach, so the operation and the radiation field can be planned wide enough to cover them.
Chemotherapy (selected high-grade cases)
Considered for large, high-grade tumors at higher risk of spreading and used for disease that has spread; not needed for most low-grade tumors.
Sarcoma specialty center care with close follow-up
Treatment at a center with a dedicated sarcoma team, plus diligent long-term follow-up, gives the best chance of a complete first removal and of catching any local recurrence early.
How radiation treatment works
Radiation therapy treats myxofibrosarcoma by delivering focused beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. For this particular sarcoma, radiation is an especially important partner to surgery, and the reason is the tumor's defining trait: its long, microscopic, finger-like tails. Myxofibrosarcoma does not grow as a tidy ball; it sends infiltrative extensions of tumor cells creeping through the surrounding tissue far beyond the edge of the mass that can be seen or felt. Those tails are easy to leave behind during surgery, which is why this is one of the sarcomas most prone to coming back where it started. Radiation addresses exactly this problem by treating a wide zone around the tumor — designed, with the help of MRI mapping, to cover the territory the tails reach — sterilizing that microscopic disease so the cancer is far less likely to recur locally and so the limb can be preserved. Radiation can be given before or after surgery. Beforehand it uses a smaller treatment area and a lower dose, can make a limb-preserving operation with adequate margins more achievable, and is associated with better long-term limb function, though it requires extra attention to wound healing. Afterward it treats a generous tumor bed at a higher dose over a larger area when preoperative radiation wasn't given. Because the target is often elongated to follow the tails, modern techniques such as intensity-modulated radiation are used to shape the dose tightly around that irregular volume while sparing the surrounding muscle, bone, and joints to preserve function. Radiation also has a role beyond the original site: when a high-grade myxofibrosarcoma spreads to a limited number of spots in the lungs, focused high-dose radiation (stereotactic body radiation) can ablate those deposits and provide durable control without surgery. In short, radiation's strength here is treating the broad zone of microscopic disease that this uniquely infiltrative tumor leaves behind — disease that surgery alone struggles to fully remove.
The main ways radiation is delivered for myxofibrosarcoma:
Preoperative (neoadjuvant) radiation
Radiation given before surgery treats the infiltrative tails using a smaller field and lower dose, can make a limb-preserving operation with adequate margins more achievable, and is associated with better long-term limb function, at the cost of more wound-healing care.
Postoperative (adjuvant) radiation
Radiation to a generous tumor bed after surgery, used when preoperative radiation wasn't given, sterilizes the microscopic disease left behind along the tails and lowers the high chance of local recurrence, at a higher dose over a larger area.
Intensity-modulated radiation (IMRT)
Shaping the beams tightly around the (often elongated) target spares surrounding muscle, bone, and joints while still covering the infiltrative tails, helping preserve limb function.
Stereotactic body radiation (SBRT) for metastases
Focused, high-dose radiation can ablate a limited number of lung metastases from high-grade tumors, offering durable control without surgery.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Infiltrative tails drive high local recurrence: Pathology and imaging studies confirm that myxofibrosarcoma's microscopic tails extend well beyond the visible tumor, explaining its high local recurrence rate and supporting wide surgery combined with radiation to cover the infiltrated zone.[1]
Myxofibrosarcoma tumor-margin and recurrence studies
Preoperative versus postoperative radiation for limb sarcomas: Randomized data show preoperative radiation uses a smaller field and lower dose with better long-term limb function but more wound-healing issues, while postoperative radiation has fewer wound problems but more late stiffness — guiding individualized timing for myxofibrosarcoma.[2]
Pre- versus post-operative radiotherapy randomized trial (extremity sarcoma)
MRI mapping improves surgical margins: Studies show that detailed MRI mapping of the infiltrative tails before surgery helps plan adequate margins and radiation fields, improving local control for this notoriously recurrence-prone sarcoma.[3]
MRI-guided planning in myxofibrosarcoma
Common questions
Why does myxofibrosarcoma come back so often, and how is that prevented? Myxofibrosarcoma's defining feature is that it sends long, microscopic, finger-like tails of tumor cells creeping through the surrounding tissue far beyond the visible mass. These tails are easy to leave behind during surgery, which is why the tumor has one of the highest local recurrence rates of any sarcoma. Two things lower that risk: a wide surgical removal — guided by MRI that maps how far the tails reach — and radiation, given before or after surgery, that treats the broad zone of microscopic disease the scalpel cannot fully capture. Together they substantially reduce the chance of the cancer returning where it started, which is why both are usually recommended.
Does a low-grade myxofibrosarcoma still need radiation? Often yes. Even though low-grade myxofibrosarcoma rarely spreads to other organs, it shares the infiltrative tails that make this tumor so prone to coming back locally. Because of that, radiation is frequently added to surgery even for low-grade tumors, to treat the microscopic disease and lower the chance of recurrence. The decision is individualized — based on the tumor's size, location, depth, and the surgical margins — but the high tendency to recur means radiation is considered more readily here than for some other low-grade sarcomas. Careful long-term follow-up is also important.
Where does myxofibrosarcoma spread, and do I need chemotherapy? When a high-grade myxofibrosarcoma spreads, it travels through the bloodstream most often to the lungs, which is why a CT scan of the chest is part of staging and follow-up. Low-grade tumors rarely spread at all. Chemotherapy is not needed for most myxofibrosarcomas; it is reserved for large, high-grade tumors at higher risk of spreading and for disease that has already spread. The main treatment for the great majority of patients is wide surgery combined with radiation to control the tumor where it started.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Myxofibrosarcoma tumor-margin and recurrence studies (no indexed identifier — see your care team) ↩
- Pre- versus post-operative radiotherapy randomized trial (extremity sarcoma) (no indexed identifier — see your care team) ↩
- MRI-guided planning in myxofibrosarcoma (no indexed identifier — see your care team) ↩